MarginsXMarginsX
Home › Markets › Health Care › PHVS

Pharvaris N.V. (PHVS)

PHVS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$32.44
-2.76% on the day
Market cap
$2.3B
Mid cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerPHVS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNetherlands
IPO year2021
SEC CIK0001830487
SEC industry codePharmaceutical Preparations
Incorporated inNetherlands

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
25.5 months
$322.4M cash at December 31, 2025
Share count, 1 year
+19.9%
2024-12-31 to 2025-12-31 · +92.8% over 3 years
Going-concern doubt
No
20-F filed April 2, 2026
Insider net buying, 12 months
-$32.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-02
Cash and burn$322.4M cash; operating cash flow -$37.9M a quarter.Report 2025-12-31
Shares outstanding65,210,590 (2025-12-31); 54,379,491 a year earlier; 33,816,459 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-08
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers Accountants N.V., Amsterdam, NetherlandsPCAOB Form AP 2026-05-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $32.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$194.2M-$151.5M$322.4MNo debt tagsNeeds four quarters20-F 2026-04-02
FY 2020
2020-12-31
Not filed-$26.0MNot filedNot filedNo debt tagsNeeds four quarters20-F 2021-04-29
FY 2019
2019-12-31
Not filed-$8.0MNot filedNot filedNo debt tagsNeeds four quarters20-F 2021-04-29
FY 2018
2018-12-31
Not filed-$4.3MNot filedNot filedNo debt tagsNeeds four quarters20-F 2021-04-29

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-08
Latest annual report20-F2026-04-02
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 331 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.0%
1 month+11.1%
3 months-2.0%
Year to date+20.2%
1 year+37.5%
From 52-week high-14.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PRGOPerrigo Company plc$16.18-0.37%$2.2B
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B
LKFTLakefront Biotherapeutics$34.79+2.38%$2.3B
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
IMNMImmunome Inc.$17.61-6.18%$2.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier